日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial

早期三阴性乳腺癌辅助化疗方案:表柔比星联合环磷酰胺序贯紫杉烷类药物联合或不联合卡铂(RJBC 1501):一项随机III期试验

Chen, Xiaosong; Huang, Jiahui; Shi, Haoting; Zhu, Juanying; Wu, Weizhu; Ye, Guolin; He, Qi; Shi, Yong; Zhang, Anqin; Xie, Xiaohong; Wang, Xiaodong; Chen, Xiangjing; Wu, Weili; Wu, Jundong; Li, Zhian; Li, Zhanwen; Dai, Yuechu; Ren, Weili; Shao, Qing; Chen, Yongan; Zeng, Yong; Zhang, Fengzhe; Dong, Shuwen; Pegram, Mark Daniel; Shen, Kunwei

Comparison of male breast cancer in China and the US: a real-world cohort study

中国与美国男性乳腺癌的比较:一项真实世界队列研究

Gao, Yuxuan; Zhang, Mengmeng; Nie, Jianyun; Ye, Guolin; Sun, Gang; Ma, Li; Wang, Hebing; Jiang, Zefei; Lin, Ying

ALKBH3-regulated m(1)A of ALDOA potentiates glycolysis and doxorubicin resistance of triple negative breast cancer cells.

ALKBH3 调控的 ALDOA 的 m(1)A 增强了三阴性乳腺癌细胞的糖酵解和阿霉素耐药性

Deng Yuhua, Chen Zhiyan, Chen Peixian, Xiong Yaming, Zhang Chuling, Wu Qiuyuan, Huang Huiqi, Yang Shuqing, Zhang Kun, He Tiancheng, Li Wei, Ye Guolin, Luo Wei, Wang Hongsheng, Zhou Dan

The features of male breast cancer in China: A real-world study

中国男性乳腺癌的特征:一项真实世界研究

Gao, Yuxuan; Zhang, Mengmeng; Sun, Gang; Ma, Li; Nie, Jianyun; Yuan, Zhongyu; Liu, Zhenzhen; Cao, Yali; Li, Jianbin; Liu, Qiang; Ye, Songqing; Chen, Bo; Song, Yuhua; Wang, Kun; Ren, Yu; Ye, Guolin; Xu, Ling; Liu, Shu; Chen, Qianjun; Li, Weiwen; Chen, Xinxin; Fu, Peifen; Wei, Wei; Guo, Baoliang; Wang, Hebing; Cai, Zhenhai; Du, Caiwen; Wu, Zhiyong; Zha, Xiaoming; Huang, Heng; Xu, Juan; Zhang, Chenglei; Shi, Yingying; Liu, Ting; Liu, Sihua; Jiang, Zefei; Lin, Ying

Single-cell transcriptomes of dissecting the intra-tumoral heterogeneity of breast cancer microenvironment

利用单细胞转录组分析解析乳腺癌微环境的肿瘤内异质性

Chen, Peixian; Liang, Kaifeng; Mao, Xiaofan; Wu, Qiuyuan; Chen, Zhiyan; Jin, Yabin; Lin, Kairong; He, Tiancheng; Yang, Shuqing; Huang, Huiqi; Ye, Guolin; Gao, Juntao; Zhou, Dan; Zeng, Zhihao

Short-term efficacy and safety of neoadjuvant pyrotinib plus taxanes for early HER2-positive breast cancer: a single-arm exploratory phase II trial

新辅助吡咯替尼联合紫杉烷类药物治疗早期 HER2 阳性乳腺癌的短期疗效和安全性:一项单臂探索性 II 期试验

Ye, Guolin; Chen, Peixian; Liu, Xiangwei; He, Tiancheng; Pivot, Xavier; Pan, Ruilin; Zhou, Dan; Zhu, Lewei; Zhang, Kun; Li, Wei; Yang, Shuqing; Lin, Jiawei; Cai, Gengxi; Huang, Huiqi

Longitudinal MRI-based fusion novel model predicts pathological complete response in breast cancer treated with neoadjuvant chemotherapy: a multicenter, retrospective study

基于纵向磁共振成像融合的新型模型预测接受新辅助化疗的乳腺癌患者的病理完全缓解:一项多中心回顾性研究

Huang, YuHong; Zhu, Teng; Zhang, XiaoLing; Li, Wei; Zheng, XingXing; Cheng, MinYi; Ji, Fei; Zhang, LiuLu; Yang, CiQiu; Wu, ZhiYong; Ye, GuoLin; Lin, Ying; Wang, Kun

circFARP1 enables cancer-associated fibroblasts to promote gemcitabine resistance in pancreatic cancer via the LIF/STAT3 axis

circFARP1 通过 LIF/STAT3 轴使癌症相关成纤维细胞促进胰腺癌的吉西他滨耐药性

Chonghui Hu #, Renpeng Xia #, Xiang Zhang #, Tingting Li #, Yuancheng Ye, Guolin Li, Rihua He, Zhihua Li, Qing Lin, Shangyou Zheng, Rufu Chen

Deep learning with biopsy whole slide images for pretreatment prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer:A multicenter study

利用活检全切片图像进行深度学习预测乳腺癌新辅助化疗后的病理完全缓解:一项多中心研究

Li, Bao; Li, Fengling; Liu, Zhenyu; Xu, FangPing; Ye, Guolin; Li, Wei; Zhang, Yimin; Zhu, Teng; Shao, Lizhi; Chen, Chi; Sun, Caixia; Qiu, Bensheng; Bu, Hong; Wang, Kun; Tian, Jie

Circulating T-Cell Repertoires Correlate With the Tumor Response in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy

循环T细胞库与接受新辅助化疗的乳腺癌患者的肿瘤反应相关

Cai, Gengxi; Guan, Zhanwen; Jin, Yabin; Su, Zuhui; Chen, Xiangping; Liu, Qing; Wang, Chunlin; Yin, Xiaoxia; Zhang, Lifang; Ye, Guolin; Luo, Wei